Skip to main content

Table 2 Univariate analysis and multivariate analysis of prognostic predictors for OS and DMFS in 127 locally unresectable HCC patients

From: Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm

Characteristics Patients OS (%) Univariate analysis Multivariate analysis DMFS (%) Univariate analysis Multivariate analysis
1-year 3-year 1-year 3-year
Gender Male 112 71.1 46.3 0.275   63.1 38.8 0.568  
Female 15 66.7 34.6    60.0 35.0   
Age, years ≥60 29 69.9 45.1 0.740   68.7 48.5 0.558  
<60 98 70.9 43.2    61.2 35.9   
AFP ≥100 ng/mL Yes 74 63.4 33.4 0.009* 0.057 55.8 28.2 0.022* 0.081
No 53 80.3 61.1    70.2 52.5   
BCLC stage A 87 67.5 45.0 0.924   60.6 37.8 0.934  
B 40 76.9 44.6    66.8 39.5   
CTP class A 111 74.0 45.3 0.112   66.1 39.4 0.099  
B 16 60.6 44.6    36.1 27.0   
TACE/TAE Yes 77 75.5 50.8 0.047* 0.017* 66.3 44.3 0.049* 0.011*
No 50 62.4 32.9    56.8 26.1   
BED10 (Gy) ≥100 44 87.8 62.0 0.005* 0.049* 80.2 50.2 0.006* 0.023*
<100 83 61.4 35.4    53.3 30.6   
Tumor size (cm) 5–10 94 77.2 47.3 0.048* 0.137 67.2 42.0 0.064 0.053
≥10 33 51.8 39.1    49.8 28.9   
EQD2 (Gy) ≥74 88 75.4 52.0 0.046* 0.051 68.0 46.3 0.008* 0.035*
<74 39 59.9 28.1    51.2 21.6   
  1. CTP Child–Turcotte–Pugh, SBRT stereotactic body radiation therapy, AFP alpha fetoprotein, BED biologically effective dose, EQD 2 equivalent dose in 2Gy fraction, OS overall survival, DMFS distant metastasis-free survival, TACE/TAE trans-arterial embolization; *P < 0.05